<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        24-5223-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Epirubicin Hydrochloride 2mg/ml Solution for Injection or Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EPIRUBICIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Intravesical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        148.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01DB03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is &lsquo;Epirubicin Hydrochloride<br />2mg/ml solution for injection or infusion&rsquo; but in the rest<br />of the leaflet it will be called &lsquo;Epirubicin Hydrochloride<br />Injection&rsquo;.<br />What Epirubicin Hydrochloride Injection is<br />Epirubicin Hydrochloride Injection is an anticancer<br />medicine. Treatment with an anticancer medicine is<br />sometimes called cancer chemotherapy. Epirubicin<br />Hydrochloride Injection is part of a group of medicines<br />called Anthracyclines. These act upon cells that are<br />actively growing, to slow or stop their growth and<br />increase the chance that the cells die.<br />What Epirubicin Hydrochloride Injection is used for<br />Epirubicin Hydrochloride Injection is used to treat a<br />variety of cancers, either alone or in combination with<br />other drugs. The way in which it is used depends upon<br />the type of cancer that is being treated. Epirubicin<br />Hydrochloride Injection is used in the treatment of<br />cancers of the breast and stomach. When injected into the<br />bladder through a tube, Epirubicin Hydrochloride<br />Injection is used to treat abnormal cells or cancers of the<br />bladder wall. It can also be used after other treatments for<br />prevention of such cells from growing again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Epirubicin Hydrochloride Injection if you<br />&bull; are allergic (hypersensitive) to Epirubicin<br />Hydrochloride or any of the other ingredients of<br />Epirubicin Hydrochloride Injection (a list of ingredients<br />can be found in Section 6)<br />&bull; are aware that your blood count is low, as Epirubicin<br />Hydrochloride Injection can lower it further<br />&bull; suffer from or have suffered from severe heart failure<br />in the past or are presently receiving treatment for this<br />&bull; have previously been treated with Epirubicin<br />Hydrochloride Injection or similar chemotherapy<br />drugs as previous treatment with these medicines can<br />increase the risk of side effects<br />&bull; suffer from an acute severe infection<br />&bull; have severe inflammation in the mouth, pharynx,<br />oesophagus and gastrointestinal tract<br />&bull; are breastfeeding or<br />&bull; have severe liver problems<br />&bull; are Pregnant<br />Tell your doctor or hospital pharmacist if any of the<br />above applies to you.<br />In any of the above cases, you should not be given<br />Epirubicin Hydrochloride Injection.<br />Epirubicin Hydrochloride Injection should not be<br />injected into the bladder if<br />&bull; you suffer from urinary infection<br />&bull; there are tumours which penetrate the bladder wall<br />&bull; your doctor has problems inserting a catheter (tube) into<br />your bladder<br />&bull; you have an inflammation of the bladder or<br />&bull; you have large volume of urine left in your bladder after<br />you attempt to empty it<br />&bull; there is blood in your urine<br />Take special care with Epirubicin Hydrochloride<br />Injection and tell your doctor if<br />&bull; you have some kidney or liver problems. You should<br />inform your doctor before treatment, as he/she needs to<br />take special care<br />&bull; you have had or you are due to have any vaccination<br />Your doctor will also be making regular checks<br />&bull; so that your blood cell count will not be too low<br />&bull; to control on the levels of uric acid in the blood<br />&bull; to check that your heart and liver are working normally<br />&bull; if you have or are to have radiotherapy to the area<br />around the heart<br />&bull; for presence of blood in your urine<br />You should inform your doctor in case you experience<br />swelling and pain in your mouth or mucous membrane.<br />It is possible that the urine will have a red colour for one<br />or two days after administration.</p><p>Using other medicines<br />Tell your doctor if you are taking or have recently taken<br />any other medicines, including medicines obtained<br />without a prescription. Especially:<br />&bull; Cimetidine (a drug usually used to reduce the acid in<br />the stomach and heartburn). Cimetidine can make the<br />effects of Epirubicin Hydrochloride Injection stronger<br />&bull; Paclitaxel and Docetaxel (used in some cancers)<br />&bull; Calcium channel blockers (medicines for the heart)<br />&bull; Interferon alfa-2b (used in some cancers and<br />lymphoma and for some yellow fever)<br />&bull; Quinine (used for treatment of malaria and for leg<br />cramps)<br />&bull; Antibiotics such as Sulphonamide and<br />Chloramphenicol<br />&bull; Antiretroviral (drugs used to treat infection by HIV)<br />&bull; Diphenylhydantoin (a drug used to treat epilepsy)<br />&bull; Painkillers such as Amidopyrine derivatives<br />&bull; Dexrazoxane (sometimes used with Doxorubicin in<br />order to decrease the risk of heart problems)<br />&bull; Dexverapamil (used to treat some heart conditions)<br />&bull; Other medicines that may affect your liver and/or heart<br />&bull; Other cancer treatments such as Doxorubicin,<br />MitomycinC, Dacarbazine, Dactinomycin and possibly<br />Cyclophosphamide and Radiotherapy.<br />&bull; Other medicines that may affect your liver e.g.<br />Barbiturates (medicines used in epilepsy or sleep<br />disorders) and Rifampicin (a medicine used to treat TB).<br />&bull; TRASTUZUMAB: Epirubicin should not be taken<br />within 24 weeks of taking Trastuzumab<br />Pregnancy and Breastfeeding<br />Epirubicin Hydrochloride Injection may cause birth defects<br />when used during pregnancy, it is important to tell your<br />doctor if you are pregnant or if you become pregnant<br />during treatment. You must not use Epirubicin<br />Hydrochloride Injection during pregnancy unless clearly<br />indicated by your doctor.<br />If you or your partner is being treated with Epirubicin<br />Hydrochloride Injection, effective birth control to prevent<br />pregnancy during treatment and for 6 months after<br />treatment is advised. If pregnancy occurs during<br />treatment, genetic consultation is recommended.<br />There is a risk of sterility due to therapy with Epirubicin<br />Hydrochloride Injection and male patients should consider<br />storage of sperm before treatment.<br />Epirubicin Hydrochloride Injection may be harmful to<br />nursing infants, therefore women must stop breastfeeding<br />before starting treatment with Epirubicin Hydrochloride<br />Injection.<br />Driving and using machines<br />Epirubicin Hydrochloride Injection may cause episodes<br />of nausea and vomiting, which can temporarily lead to an<br />impairment of the ability to drive or use machines.<br />Important information about some of the ingredients<br />of Epirubicin Hydrochloride Injection<br />This medicinal product contains less than 1mmol sodium<br />(23mg) per ml, i.e. essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Epirubicin Hydrochloride Injection will be given to you<br />by a doctor or nurse, either into a vein or directly into<br />your bladder. Your doctor will decide the correct dose<br />and number of days treatment you receive, this will<br />depend on the type of cancer you have, your health,<br />height, weight, how well your liver is working and any<br />other treatment you may receive.<br />By injection or infusion into a vein<br />Epirubicin Hydrochloride Injection may be given as an<br />injection into a vein over 3-5 minutes. It may also be<br />diluted before it is infused slowly, usually via a drip into<br />a vein over 30 minutes.<br />By being put into the bladder<br />If the injection is given into the bladder, you should not<br />drink any fluids for 12 hours before treatment so that<br />your urine will not dilute the drug too much. The solution<br />should be kept in your bladder for 1-2 hours after<br />installation. You will need to turn occasionally to make<br />sure all parts of the bladder are exposed to the drug.<br />Care should be taken to ensure that the contents of the<br />bladder, when emptied, do not come into contact with the<br />skin. In case of skin contact, thoroughly wash the affected<br />area with soap and water but do not scrub.<br />Your doctor will regularly check your blood for any<br />unwanted effects. To detect any possible heart damage<br />your doctor will also monitor your heart for several<br />weeks after the treatment.<br />Regular checks by your doctor during Epirubicin<br />Hydrochloride Injection treatment<br />During treatment your doctor will be making regular<br />checks of your<br />&bull; Blood: to check for low blood cell count that may need<br />treatment.<br />&bull; Heart function: heart damage can occur when high<br />doses of Epirubicin Hydrochloride Injection are given.<br />This may not be detected for several weeks, so regular<br />tests may be required during this period.<br />&bull; Liver: using blood tests to check that this medicine is<br />not adversely affecting the way it functions.<br />&bull; Blood uric acid levels: Epirubicin Hydrochloride<br />Injection may increase uric acid levels in the blood<br />which might cause gout. Another medicine may be<br />given if your uric acid levels are too high.<br />If you receive more Epirubicin Hydrochloride<br />Injection than you should:<br />High doses can worsen side effects like sores in the<br />mouth or may decrease the number of white blood cells<br />(which fight infection) and platelets (these help the blood<br />to clot) in the blood. Should this happen, you may need</p><p>antibiotics or blood transfusions. Mouth ulcers can be<br />treated to make them less uncomfortable as they heal.<br />Please tell your doctor if you have any concerns.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Epirubicin Hydrochloride Injection<br />can cause side effects, although not everybody gets them.<br />If any of the following side effects happen when<br />Epirubicin is given by infusion into a vein, tell your<br />doctor immediately, as these are very serious side effects.<br />You may need urgent medical attention in below cases<br />&bull; redness, pain or swelling at the injection site; tissue<br />damage may occur after accidental injection outside a vein<br />&bull; symptoms of heart problems such as chest pain,<br />shortness of breath, swelling of your ankles (these<br />effects may occur up to several weeks after finishing<br />treatment with Epirubicin)<br />&bull; severe allergic reaction, symptoms include faintness,<br />skin rash, swelling of the face and difficulty in<br />breathing or wheezing<br />&bull; Infection and inflammation of the bladder<br />In some cases collapse may occur. If you experience any<br />of the following, tell your doctor as soon as possible:<br />Very common (these may affect at least 1 in 10 people):<br />&bull; White blood cell count (which fight infection) can drop,<br />which increases the chance of infections and fever<br />&bull; A low red blood cell count (anaemia) that can leave you<br />feeling tired and lethargic<br />&bull; Hair loss may be quite severe. Beard growth may stop<br />in men. Hair normally re-grows when your treatment<br />course ends<br />&bull; Red discolouration of urine (which is normal and<br />related to the colour of the medicine). You should<br />inform your doctor if it does not stop in a few days or<br />you think there is blood in your urine<br />Common (these may affect between 1 in 100 and 1 in<br />10 people):<br />&bull; Infections<br />&bull; Allergic reactions<br />&bull; Feeling or being sick (nausea or vomiting)<br />&bull; Diarrhoea (which can result in dehydration)<br />&bull; Feeling thirsty (dehydration)<br />&bull; Loss of appetite<br />&bull; Abdominal pain<br />&bull; Heartburn<br />&bull; Inflammation of the gullet (oesophagitis)<br />&bull; High levels of pigments in the mouth<br />&bull; Swelling and pain in the mouth<br />&bull; Ulcers involving the lips and/or tongue and/or under the<br />tongue, which may not appear until 3-10 days after<br />treatment<br />&bull; Hot flushes<br />&bull; Changes in blood cells causing bleeding<br />&bull; Fever<br />&bull; Pain, redness, burning or stinging sensation at injection<br />site<br />&bull; Irritation of the bladder or damage to the bladder wall<br />(called necrosis)<br />Uncommon (these may affect between 1 in 10,000 and 1<br />in 100 people):<br />&bull; Platelets (cells that help the blood to clot) can be affected<br />which could make you bruise or bleed more easily. It is<br />important to seek medical advice if this happens<br />&bull; Swelling, redness, leg pain, which can be associated<br />with blood clots<br />&bull; Vein inflammation including blood clotting<br />(thrombophlebitis)</p><p>Rare (these may affect between 1 in 10,000 and 1 in<br />1,000 people):<br />&bull; When given in combination with other anticancer drugs,<br />some patients have developed a rare leukaemia (cancer<br />of white blood cells) after completing treatment<br />&bull; Tiredness, weakness and feeling cold<br />&bull; Gasping for air, shortness of breath, swelling of<br />abdomen, legs or ankles, fluid in lungs (signs of<br />congestive heart failure)<br />&bull; ECG abnormalities, irregular heartbeat, heart muscle<br />disease<br />&bull; Hives (urticaria)<br />&bull; Fever and/or chills<br />&bull; Dizziness<br />&bull; Absence of menstrual periods (amenorrhea)<br />&bull; Low sperm count<br />&bull; Increase uric acid levels in the blood which might cause<br />gout<br />&bull; Changes in heart or liver function<br />&bull; Fever with an extreme elevation of body temperature<br />(hyperpyrexia)<br />&bull; Feeling of general discomfort or uneasiness (malaise)<br />Not known (cannot be estimated from the available data)<br />&bull; Blood infection<br />&bull; Pneumonia<br />&bull; Internal bleeding<br />&bull; Inflammation to the eye (conjunctivitis and keratitis)<br />&bull; Shock<br />&bull; Discolouration of skin and nails<br />&bull; Sensitive to light<br />&bull; Blood clots, including a clot in the lungs which causes<br />chest pain and breathlessness<br />If any of the side effects gets serious, or if you notice any<br />side effects not listed in this leaflet, please tell your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.<br />Keep the vial in the outer pack in order to protect from light.<br />Do not use Epirubicin Hydrochloride Injection after the<br />expiry date, which is stated on the pack. The expiry date<br />refers to the last day of that month.<br />Do not use Epirubicin Hydrochloride Injection if you&nbsp;notice any visible signs of deterioration.<br />Medicines should not be disposed of via wastewater or<br />household waste.<br />Ask your pharmacist how to dispose medicines no longer<br />required. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in Epirubicin Hydrochloride<br />Injection is Epirubicin Hydrochloride.<br />Each ml contains 2mg Epirubicin Hydrochloride.<br />Other ingredients are sodium chloride, hydrochloric acid<br />(for pH adjustment) and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Epirubicin Hydrochloride Injection is a clear, red
coloured solution.
Pack sizes:
1 x 5ml vial (10mg/5ml)
1 x 10ml vial (20mg/10ml)
1 x 25ml vial (50mg/25ml)
1 x 50ml vial (100mg/50ml)
1 x 100ml vial (200mg/100ml)
Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow, Middlesex<br />HA1 4HF, United Kingdom<br />Tel: +44 208 863 1427<br />Fax: +44 208 863 1426<br />E-mail: mena-info@accord-healthcare.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>غير متوفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            غير متوفر
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epirubicin Hydrochloride 2mg/ml solution for injection or infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 2mg Epirubicin Hydrochloride.
Each 5/10/25/50/100 ml vial contains 10/20/50/100/200 mg Epirubicin Hydrochloride.
Excipient:
Contains sodium 3.54mg/ml (0.154mmol).
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection or infusion
A clear red solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epirubicin is used in the treatment of a range of neoplastic conditions including:<br />&bull; Carcinoma of the breast<br />&bull; Gastric cancer</p><p>When administered intravesically, Epirubicin has been shown to be beneficial in the treatment of<br />&bull; Papillary transitional cell carcinoma of the bladder<br />&bull; Carcinoma-in-situ of the bladder.<br />&bull; Prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epirubicin is for intravenous or intravesical use only.<br />The safety and efficacy of Epirubicin in children has not been established.<br />Intravenous administration<br />It is advisable to administer Epirubicin via the tubing of a free-running intravenous saline infusion after checking that the needle is properly placed in the vein. Care should be taken to avoid extravasation (see section 4.4). In case of extravasation, administration should be stopped immediately.<br />Conventional dose<br />When Epirubicin is used as a single agent, the recommended dosage in adults is 60-90mg/m2 body area. Epirubicin should be injected intravenously over 3-5 minutes. The dose should be repeated at 21-day intervals, depending upon the patient&#39;s haematomedullary status.<br />If signs of toxicity, including severe neutropenia/neutropenic fever and thrombocytopenia occur (which could persist at day 21), dose modification or postponement of the subsequent dose may be required.<br />High dose<br />Epirubicin as a single agent for the high dose treatment of lung cancer should be administered according to the following regimens:<br />&bull; Small cell lung cancer (previously untreated): 120mg/m2 day 1, every 3 weeks.<br />For high dose treatment, Epirubicin may be given as an intravenous bolus over 3-5 minutes or as an infusion of up to 30 minutes duration.<br />&bull; For Non-small cell lung cancer (squamous, large cell, and adenocarcinoma previously untreated): 135 mg/m2 day 1 or 45 mg/m2 day 1, 2 and 3 every 3 weeks<br />Breast Cancer<br />In the adjuvant treatment of early breast cancer patients with positive lymph nodes, intravenous doses of Epirubicin ranging from 100mg/m2 (as a single dose on day 1) to 120mg/m2 (in two divided doses on days 1 and 8) every 3-4 weeks, in combination with intravenous cyclophosphamide and 5-Fluorouracil and oral Tamoxifen (in accordance with local guidelines) are recommended.<br />Lower doses (60-75mg/m2 for conventional treatment and 105-120mg/m2 for high dose treatment) are recommended for patients whose bone marrow function has been impaired by previous chemotherapy or radiotherapy, by age, or neoplastic bone marrow infiltration. The total dose per cycle may be divided over 2-3 successive days.<br />The following doses of Epirubicin are commonly used in monotherapy and combination chemotherapy for various tumours, as shown:</p><p>Epirubicin Dose (mg/m2 )a<br />Cancer Indication<br />Monotherapy<br />Combination Therapy<br />Ovarian cancer<br />60&ndash;90<br />50&ndash;100<br />Gastric cancer<br />60&ndash;90<br />50<br />SCLC<br />120<br />120<br />Bladder cancer<br />50mg/50ml or 80mg/50ml<br />(carcinoma in situ)<br />Prophylaxis:<br />50mg/50ml weekly for 4 weeks then monthly for 11months</p><p>aDoses generally given Day 1 or Day 1, 2 and 3 at 21-day intervals<br />For high dose treatment, Epirubicin may be given as an intravenous bolus over 3-5 minutes or as an infusion of up to 30 minutes duration.<br />Combination therapy<br />If Epirubicin is used in combination with other cytotoxic products, the dose should be reduced accordingly. Commonly used doses are shown in the table above. In establishing the maximal cumulative doses of Epirubicin (usually: 720&ndash; 1000mg/m2), any concomitant therapy with potentially cardiotoxic drugs should be taken into account.<br />Impaired liver function<br />The major route of elimination of Epirubicin is the hepatobiliary system. In patients with impaired liver function the dose should be reduced based on serum bilirubin levels as follows:</p><p>Serum Bilirubin<br />AST*<br />Dose Reduction<br />1.4 &ndash; 3 mg/100 ml<br />50%<br />&gt; 3 mg/100 ml<br />&gt; 4 times upper normal limit<br />75%</p><p>*AST &ndash; aspartate aminotransferase</p><p>Impaired renal function<br />Moderate renal impairment does not appear to require a dose reduction in view of the limited amount of Epirubicin excreted by this route. Lower starting doses should be considered in patients with severe renal impairment (serum creatinine &gt;450&mu;mol/l).<br />Intravesical administration<br />Epirubicin can be given by intravesical administration for the treatment of superficial bladder cancer and carcinoma-in-situ. It should not be given intravesically for the treatment of invasive tumours that have penetrated the bladder wall, systemic therapy or surgery is more appropriate in these situations (see section 4.3). Epirubicin has also been successfully used intravesically as a prophylactic agent after transurethral resection of superficial tumours to prevent recurrence.<br />For the treatment of superficial bladder cancer the following regimen is recommended, using the dilution table below:<br />8 weekly instillations of 50mg/50ml (diluted with saline or distilled sterile water).<br />If local toxicity is observed: A dose reduction to 30mg/50 ml is advised.<br />Carcinoma-in-situ: Up to 80mg/50ml (depending on individual tolerability of the patient)<br />For prophylaxis: 4 weekly administrations of 50mg/50ml followed by 11 monthly instillations at the same dose.<br />DILUTION TABLE FOR BLADDER INSTILLATION SOLUTIONS<br />Dose Epirubicin required<br />Volume of 2mg/ml Epirubicin hydrochloride injection<br />Volume of diluent sterile water for injection or 0.9% sterile saline<br />Total volume for bladder installation<br />30mg<br />15ml<br />35ml<br />50ml<br />50mg<br />25ml<br />25ml<br />50ml<br />80mg<br />40ml<br />10ml<br />50ml<br />The solution should be retained intravesically for 1-2 hour. To avoid undue dilution with urine, the patient should be instructed not to drink any fluid in the 12 hours prior to instillation. During the instillation, the patient should</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epirubicin is contraindicated in:
• Patients who have demonstrated hypersensitivity to the active substance or to any of the excipients, other Anthracyclines or Anthracenediones.
• Lactation
Intravenous use:
• Patients with persistent myelosuppression
• Patients with marked myelosuppression induced by previous treatment with either other anti-neoplastic agents or radiotherapy to the mediastinal pericardial area and/or who are under medical treatment with potentially cardiotoxic medicinal products (see section 4.5).
• Patients treated with maximal cumulative doses of Epirubicin and/or other Anthracyclines (e.g. Doxorubicin or Danuorubicin) and Anthracenediones (see section 4.4).
• Patients with current or previous history of cardiac impairment and myocardial infraction.
• Patients with acute systemic infections.
• Sever liver impairment.
• Severe arrhythmias
• Unstable angina pectoris
• Myocardiopathy
Epirubicin is contraindicated for intravesical administration in case of:
• Urinary tract infections.
• Invasive tumours penetrating the bladder.
• Catheterisation problems.
• Inflammation of the bladder.
• Hematuria
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Epirubicin should only be administered under the supervision of a qualified physician who is experienced in the use of cytotoxic therapy. Diagnostic and treatment facilities should be readily available for management of therapy and possible complications due to myelosuppression, especially following treatment with higher doses of Epirubicin.<br />Patients should recover from acute toxicities (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) of prior cytotoxic treatment before beginning treatment with Epirubicin.<br />While treatment with high doses of Epirubicin (e.g., &ge; 90mg/m2 every 3 to 4 weeks) causes adverse events generally similar to those seen at standard doses (&lt; 90mg/m2 every 3 to 4 weeks), the severity of the neutropenia and stomatitis/mucositis may be increased. Treatment with high doses of Epirubicin does require special attention for possible clinical complications due to profound myelosuppression.<br />Cardiac Function<br />Cardiotoxicity is a risk of Anthracycline treatment that may be manifested by early (i.e., acute) or late (i.e., delayed) events.<br />Early (i.e., Acute) Events<br />Early cardiotoxicity of Epirubicin consists mainly of sinus tachycardia and/or electrocardiogram (ECG) abnormalities such as non-specific ST-T wave changes. Tachyarrhythmias, including premature ventricular contractions, ventricular tachycardia, and bradycardia, as well as atrioventricular and bundle-branch block have also been reported. These effects do not usually predict subsequent development of delayed cardiotoxicity, are rarely of clinical importance, and are generally not a consideration for the discontinuation of Epirubicin treatment.</p><p>Late (i.e., Delayed) Events<br />Delayed cardiotoxicity usually develops late in the course of therapy with Epirubicin or within 2 to 3 months after treatment termination, but later events (several months to years after completion of treatment) have also been reported. Delayed cardiomyopathy is manifested by reduced left ventricular ejection fraction (LVEF) and/or signs and symptoms of congestive heart failure (CHF) such as dyspnoea, pulmonary oedema, dependent oedema, cardiomegaly and hepatomegaly, oliguria, ascites, pleural effusion, and gallop rhythm. Life threatening CHF is the most severe form of Anthracycline-induced cardiomyopathy and represents the cumulative dose-limiting toxicity of the drug.<br />The risk of developing CHF increases rapidly with increasing total cumulative doses of Epirubicin in excess of 900mg/m2; this cumulative dose should only be exceeded with extreme caution (see section 5.1).<br />Cardiac function should be assessed before patients undergo treatment with Epirubicin and must be monitored throughout therapy to minimize the risk of incurring severe cardiac impairment. The risk may be decreased through regular monitoring of LVEF during the course of treatment with prompt discontinuation of Epirubicin at the first sign of impaired function. The appropriate quantitative method for repeated assessment of cardiac function (evaluation of LVEF) includes multi-gated radionuclide angiography (MUGA) or echocardiography (ECHO). A baseline cardiac evaluation with an ECG and either a MUGA scan or an ECHO is recommended, especially in patients with risk factors for increased cardiotoxicity. Repeated MUGA or ECHO determinations of LVEF should be performed, particularly with higher, cumulative Anthracycline doses. The technique used for assessment should be consistent throughout follow up.<br />Given the risk of cardiomyopathy, a cumulative dose of 900mg/m2 Epirubicin should be exceeded only with extreme caution.<br />Risk factors for cardiac toxicity include active or dormant cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other Anthracyclines or Anthracenediones, and concomitant use of other drugs with the ability to suppress cardiac contractility or cardiotoxic drugs (e.g., Trastuzumab) (see section 4.5).<br />Cardiac function monitoring must be particularly strict in patients receiving high cumulative doses and in those with risk factors. However, cardiotoxicity with Epirubicin may occur at lower cumulative doses whether or not cardiac risk factors are present. It is probable that the toxicity of Epirubicin and other Anthracyclines or Anthracenediones is additive.<br />Delayed Cardiomyopathy induced by anthracyclines is associated with persistent reduction of the QRS voltage, prolongation beyond normal limits of the systolic interval (PEP) and a reduction of the ejection fraction (LVEF). Electrocardiogram (ECG) changes may be indicative of anthracycline-induced cardiomyopathy, but ECG is not a sensitive or specific method for following anthracycline-related cardiotoxicity<br />Haematologic Toxicity<br />As with other cytotoxic agents, Epirubicin may produce myelosuppression. Haematologic profiles should be assessed before and during each cycle of therapy with Epirubicin, including differential white blood cell (WBC) counts. A dose-dependent, reversible leucopoenia and/or granulocytopenia (neutropenia) is the predominant manifestation of Epirubicin haematologic toxicity and is the most common acute dose-limiting toxicity of this drug. Leucopoenia and neutropenia are generally more severe with high-dose schedules, reaching the nadir in most cases between days 10 and 14 after drug administration; this is usually transient with the WBC/neutrophil counts returning to normal values in most cases by day 21. Thrombocytopenia and anaemia may also occur. Clinical consequences of severe myelosuppression include fever, infection, sepsis/septicaemia, septic shock, haemorrhage, tissue hypoxia, or death.<br />Secondary Leukaemia<br />Secondary leukaemia, with or without a preleukaemic phase, has been reported in patients treated with Anthracyclines, including Epirubicin. Secondary leukaemia is more common when such drugs are given in combination with DNA-damaging antineoplastic agents, in combination with radiation treatment, when patients have been heavily pre-treated with cytotoxic drugs, or when doses of the Anthracyclines have been escalated. These leukaemia&#39;s can have a 1 to 3 year latency period. (See section 5.1).</p><p>Gastrointestinal<br />Epirubicin is emetogenic. Mucositis/stomatitis generally appears early after drug administration and, if severe, may progress over a few days to mucosal ulcerations. Most patients recover from this adverse event by the third week of therapy.<br />Liver Function<br />The major route of elimination of Epirubicin is the hepatobiliary system. Serum total bilirubin and AST levels should be evaluated before and during treatment with Epirubicin. Patients with elevated Bilirubin or AST may experience slower clearance of drug with an increase in overall toxicity. Lower doses are recommended in these patients (see sections 4.2 and 5.2). Patients with severe hepatic impairment should not receive Epirubicin (see section 4.3).<br />Renal Function<br />Serum creatinine should be assessed before and during therapy. Dosage adjustment is necessary in patients with serum creatinine &gt; 5mg/dL (see section 4.2).<br />Epirubicin may impart a red colour to the urine for one or two days following administration.<br />Effects at Site of Injection<br />Phlebosclerosis may result from an injection into a small vessel or from repeated injections into the same vein. Following the recommended administration procedures may minimize the risk of phlebitis/thrombophlebitis at the injection site (see section 4.2).<br />Extravasation<br />Extravasation of Epirubicin during intravenous injection may produce local pain, severe tissue lesions (vesication, severe cellulitis) and necrosis. Should signs or symptoms of extravasation occur during intravenous administration of Epirubicin, the drug infusion should be discontinued immediately. The patient&#39;s pain may be relieved by cooling down the area and keeping it cool for 24 hours. The patient should be monitored closely during the subsequent period of time, as necrosis may occur after several weeks extravasation occurs, a plastic surgeon should be consulted with a view to possible excision.<br />Other<br />As with other cytotoxic agents, thrombophlebitis and thromboembolic phenomena, including pulmonary embolism (in some cases fatal), have been coincidentally reported with the use of Epirubicin<br />Tumour-Lysis Syndrome<br />Epirubicin may induce hyperuricaemia because of the extensive purine catabolism that accompanies rapid drug-induced lysis of neoplastic cells (tumour-lysis syndrome). Blood uric acid levels, potassium, calcium phosphate, and creatinine should be evaluated after initial treatment. Hydration, urine alkalinization, and prophylaxis with Allopurinol to prevent hyperuricaemia may minimize potential complications of tumour-lysis syndrome.<br />Immunosuppressant Effects/Increased Susceptibility to Infections<br />Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including Epirubicin, may result in serious or fatal infections. (see section 4.5).<br />Reproductive system<br />Epirubicin can cause genotoxicity. Men and women treated with Epirubicin should adopt appropriate contraceptive measures. Patients desiring to have children after completion of therapy should be advised to obtain genetic counselling if appropriate and available.<br />Additional Warnings and Precautions for Other Routes of Administration<br />Intravesical route<br />Administration of Epirubicin may produce symptoms of chemical cystitis (such as dysuria, polyuria, nocturia, stranguria, haematuria, bladder discomfort, necrosis of the bladder wall) and bladder constriction. Special attention is required for catheterization problems (e.g urethral obstruction due to massive intravesical tumours).</p><p>Intra-arterial route<br />Intra-arterial administration of Epirubicin (transcatheter arterial embolization for the localized or regional therapies of primary hepatocellular carcinoma or liver metastases) may produce (in addition to systemic toxicity qualitatively similar to that observed following intravenous administration of Epirubicin) localized or regional events which include gastroduodenal ulcers (probably due to reflux of the drugs into the gastric artery) and narrowing of bile ducts due to drug-induced sclerosing cholangitis. This route of administration can lead to widespread necrosis of the perfused tissue.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epirubicin is mainly used in combination with other anticancer agents. Additive toxicity may occur especially with regard to bone marrow/hematologic and gastrointestinal effects (see section 4.4). The use of Epirubicin in combination chemotherapy with other potentially cardiotoxic drugs, as well as the concomitant use of other cardioactive compounds (e.g., Calcium Channel Blockers), requires monitoring of cardiac function throughout treatment.<br />Epirubicin is extensively metabolized by the liver. Changes in hepatic function induced by concomitant therapies may affect Epirubicin metabolism, pharmacokinetics, therapeutic efficacy and/or toxicity (see section 4.4 Special warnings and precautions for use).<br />Anthracyclines including Epirubicin should not be administered in combination with other cardiotoxic agents unless the patient&#39;s cardiac function is closely monitored. Patients receiving Anthracyclines after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as Trastuzumab, may also be at an increased risk of developing cardiotoxicity. The half-life of Trastuzumab is approximately 28.5 days and may persist in the circulation for up to 24 weeks. Therefore, physicians should avoid Anthracycline-based therapy for up to 24 weeks after stopping Trastuzumab when possible. If Anthracyclines are used before this time, careful monitoring of cardiac function is recommended.<br />Vaccination with a live vaccine should be avoided in patients receiving Epirubicin. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.<br />Cimetidine 400mg bid given prior to Epirubicin 100mg/m2 every 3 weeks led to a 50% increase in Epirubicin AUC and a 41% increase in Epirubicinol AUC (latter p&lt;0.05). The AUC of the 7-deoxy-Doxorubicinol Aglycone and liver blood flow were not reduced, so results are not explained by reduced cytochrome P-450 activity. Epirubicin used in combination with other cytotoxic agents may result in additive myelotoxicity.<br />When given prior to Epirubicin, Paclitaxel can cause increased plasma concentrations of unchanged Epirubicin and its metabolites, the latter being, however, neither toxic nor active. Coadministration of Paclitaxel or Docetaxel did not affect the pharmacokinetics of Epirubicin when Epirubicin was administered prior to the Taxanes.<br />This combination may be used if using staggered administration between the two agents. Infusion of Epirubicin and Paclitaxel should be performed with at least a 24 hour interval between the 2 agents.<br />Dexverapamil may alter the pharmacokinetics of Epirubicin and possibly increase its bone marrow depressant effects.<br />One study found that Docetaxel may increase the plasma concentrations of Epirubicin metabolites, when administered immediately after Epirubicin.<br />Quinine may accelerate the initial distribution of Epirubicin from blood in to the tissues and may have an influence on the red blood cells partitioning of Epirubicin.<br />The coadministration of Interferon &alpha;2b may cause a reduction in both the terminal elimination half-life and the total clearance of Epirubicin.<br />The possibility of a marked disturbance of haematopoiesis needs to be kept in mind with a (pre-) treatment with agents which influence the bone marrow (i.e. cytostatic agents, Sulphonamide, Chloramphenicol, Diphenylhydantoin, amidopyrine dervatives, antiretroviral agents).<br />It is not recommended that Epirubicin Hydrochloride 2mg/ml Injection be mixed with other medicinal products<br />Drug interactions with Epirubicin have been observed with Dexrazoxane</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Impairment of Fertility<br />Epirubicin could induce chromosomal damage in human spermatozoa. Men undergoing treatment with Epirubicin should use effective contraceptive methods and if appropriate and available, seek advice on sperm preservation due to the possibility of irreversible infertility caused by therapy.<br />Epirubicin may cause amenorrhea or premature menopause in premenopausal women.<br />Due to the genotoxicity effects of Epirubicin, male patients are advised not to father a child during and up to 6-months following the discontinuation of Epirubicin treatment.<br />Pregnancy<br />Experimental data in animals suggest that Epirubicin may cause foetal harm when administered to a pregnant woman. If Epirubicin is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the foetus.<br />There are no studies in pregnant women. Epirubicin should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>Lactation<br />It is unknown whether Epirubicin is excreted in human breast milk. Because many drugs, including other Anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Epirubicin, mothers should discontinue nursing prior to taking this drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no reports of particular adverse events relating to the effects on ability to drive and to use machines. Epirubicin may cause episodes of nausea and vomiting, which can temporarily lead to an impairment of the ability to drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The estimation of frequency: Very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1,000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1,000); very rare (&lt;1/10,000) not known (cannot be estimated from the available data).<br />More than 10% of treated patients can expect to develop undesirable effects. The most common undesirable effects are myelosuppression, gastrointestinal side effects, anorexia, alopecia, infection.<br />Infections and infestations<br />Common: Infections<br />Not known: pneumonia, sepsis and septic shock may occur as a result of myelosuppression.<br />Neoplasms benign, malignant and unspecified (including cysts and polyps)<br />Rare: Acute lymphocytic leukaemia, Secondary acute myeloid leukaemia with or without a pre-leukaemic phase in patients treated with Epirubicin in combination with DNA-damaging antineoplastic agents. These leukaemia&#39;s have short (1-3 years) latency.<br />Blood and lymphatic system disorder<br />Very common: Myelosuppression* (leucopoenia, granulocytopenia and neutropenia, anaemia and febrile neutropenia).<br />Uncommon: Thrombocytopenia.<br />Not known: Haemorrhage and tissue hypoxia as result of myelosuppression.<br />* High doses of Epirubicin have been safely administered in a large number of untreated patients having various solid tumours and have caused adverse events which are no different from those seen at conventional doses with the exception of reversible severe neutropenia (&lt; 500 neutrophils/mm3 for &lt; 7&nbsp;days) which occurred in the majority of patients. Only few patients required hospitalization and supportive therapy for severe infectious complications at high doses.<br />Immune system disorders<br />Rare: Anaphylaxis.<br />Metabolism and nutrition disorders<br />Common: Anorexia, dehydration.<br />Rare: Hyperuricaemia (as a result of rapid lysis of neoplastic cells) (see section 4.4).<br />Nervous system disorders<br />Rare: Dizziness<br />Eye disorders<br />Not known: Conjunctivitis, keratitis<br />Cardiac disorders<br />Rare: Cardiotoxicity (ECG changes, tachycardia, arrhythmia, cardiomyopathy, congestive heart failure (dyspnoea, oedema, enlargement of the liver, ascites, pulmonary oedema, pleural effusion, gallop rhythm), ventricular tachycardia, bradycardia, AV block, bundle-branch block) (see section 4.4).<br />Vascular disorders<br />Common: Hot flushes.<br />Uncommon: Phlebitis, Thrombophlebitis.<br />Not known: Shock, Coincidental cases of thromboembolic events (including pulmonary embolism (in isolated cases with fatal outcome)) have occurred.<br />Gastrointestinal disorders<br />Common: Mucositis may appear 5-10 days after the start of treatment and usually involves stomatitis with areas of painful erosions, ulceration and bleedings, mainly along the side of the tongue and the sublingual mucosa, oesophagitis, vomiting, diarrhoea, nausea.<br />Skin and subcutaneous tissue disorders<br />Very Common: Alopecia<br />Rare: Urticaria<br />Not Known: Local toxicity, rash, itch, skin changes, erythema, flushes, skin and nail hyperpigmentation, photosensitivity, hypersensitivity to irradiated skin (radiation-recall reaction).<br />Renal and urinary disorders<br />Very common: Red colouration of urine for 1 to 2 days after administration.<br />Reproductive system and breast disorders<br />Rare: Amenorrhea, azoospermia.<br />General disorders and administration site conditions<br />Common: Redness along the infusion vein. Phlebosclerosis, Local pain and tissue necrosis may occur (following accidental paravenous injection).<br />Rare: Fever, chills, hyperpyrexia, malaise, asthenia, weakness.<br />Investigations<br />Rare: Increased Transaminase levels.<br />Not Known: Asymptomatic drops in left ventricular ejection fraction.<br />Injury, poisoning and procedural complications<br />Common: Chemical cystitis, in some cases haemorrhagic, is observed following intravesical administration (see section 4.4).</p><p>Intravesical administration<br />As only a small amount of active ingredient is reabsorbed after intravesical instillation, severe systemic adverse drug reactions as well as allergic reactions are rare. Commonly reported are local reactions like burning sensation and frequent voiding (Pollakiuria). Occasional bacterial or chemical cystitis have been reported (see section 4.4). These ADRs are mostly reversible.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute overdosage with Epirubicin will result in severe myelosuppression (mainly leucopoenia and thrombocytopenia), gastrointestinal toxic effects (mainly mucositis) and acute cardiac complications. Latent cardiac failure has been observed with Anthracyclines several months to years after completion of treatment (see section 4.4). Patients must be carefully monitored. If signs of cardiac failure occur, patients should be treated according to conventional guidelines.<br />Treatment<br />Symptomatic: Treatment should aim to support the patient during this period and should utilize such measures as blood transfusion and reverse barrier nursing. Delayed cardiac failure has been seen with the Anthracyclines up to 6 months after the overdose. Patients should be observed carefully and should, if signs of cardiac failure arise, be treated along conventional lines. Epirubicin is not dialyzable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anthracyclines and related substances ATC code: L01D B03.<br />The mechanism of action of Epirubicin is related to its ability to bind to DNA. Cell culture studies have shown rapid cell penetration, localization in the nucleus and inhibition of nucleic acid synthesis and mitosis. Epirubicin has proved to be active on a wide spectrum of experimental tumours including L1210 and P388 leukaemias, sarcomas SA180 (solid and ascitic forms), B16 melanoma, mammary carcinoma, Lewis lung carcinoma and colon carcinoma 38. It has also shown activity against human tumours transplanted into athymic nude mice (melanoma, mammary, lung, prostatic and ovarian carcinomas).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients with normal hepatic and renal function, plasma levels after intravenous injection of 60-150mg/m2 of the drug follow a tri-exponential decreasing pattern with a very fast first phase and a slow terminal phase with a mean half-life of about 40 hours. These doses are within the limits of pharmacokinetic linearity both in terms of plasma clearance values and metabolic pathway. The major metabolites that have been identified are Epirubicinol (13-OH Epirubicin) and Glucuronides of Epirubicin and Epirubicinol.<br />In a pharmacokinetic study of patients with carcinoma in situ in the bladder the plasma levels of Epirubicin after intravesical administration are typically low (&lt;10mg/ml). A significant systemic resorption is therefore&nbsp;not presumed. In patients with mucous membrane lesions in the bladder (e.g. tumour, cystitis, operations) an increased resorption rate may be expected.<br />The 4&#39;-O-glucuronidation distinguishes Epirubicin from Doxorubicin and may account for the faster elimination of Epirubicin and its reduced toxicity. Plasma levels of the main metabolite, the 13-OH derivative (Epirubicinol) are consistently lower and virtually parallel those of the unchanged drug.<br />Epirubicin is eliminated mainly through the liver; high plasma clearance values (0.9 l/min) indicate that this slow elimination is due to extensive tissue distribution.<br />Urinary excretion accounts for approximately 9-10% of the administered dose in 48 hours.<br />Biliary excretion represents the major route of elimination, about 40% of the administered dose being recovered in the bile in 72 hours. The drug does not cross the blood brain barrier</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following repeated dosing with Epirubicin, the target organs in rat, rabbit and dog were the haemolymphopoietic system, GI tract, kidney, liver and reproductive organs.<br />Epirubicin was also cardiotoxic in the rat, rabbit and dog.<br />Epirubicin, like other Anthracyclines, was genotoxic, embryotoxic and carcinogenic in rats.<br />No malformations were seen in rats or rabbits, but like other Anthracyclines and cytotoxic drugs, Epirubicin must be considered potentially teratogenic.<br />A local tolerance study in rats and mice showed extravasation of Epirubicin causes tissue necrosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride<br />Hydrochloric acid (For pH adjustment)<br />Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolonged contact of the medicinal product with any solution of alkaline pH (including sodium bicarbonate solutions) should be avoided; this will result in hydrolysis (degradation) of the active substance. Only the diluents detailed in section 6.6 should be used.<br />Neither the injection nor any diluted solution should be mixed with any other drugs. A physical incompatibility with heparin has been reported.<br />Epirubicin should not be mixed with other drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life of the product as package for sale
24 months.
Shelf life after first opening the container
The vials are for single use only and any unused portion must be discarded after use. From a microbiological point of view, the product should be used immediately after the first penetration of the rubber stopper. If not used immediately, in use storage times and conditions are the responsibility of the user.
Shelf life after dilution of the solution for injection
Epirubicin Hydrochloride 2mg/ml Injection may be further diluted, under aseptic conditions, in Glucose 5% or Sodium Chloride 0.9% and administered as an intravenous infusion. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not normally be longer than 24 hours at 2°-8°C, unless dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.<br />Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.<br />Keep the vial in the outer carton in order to protect from light.<br />For storage after dilution, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The active ingredient in Epirubicin Injection is Epirubicin Hydrochloride.<br />Each ml contains 2mg Epirubicin Hydrochloride.<br />Other ingredients include sodium chloride, hydrochloric acid and water for injection.<br />Epirubicin Injection is a clear, red coloured solution.<br />Pack sizes:<br />1 x 5ml vial (10mg/5ml)<br />1 x 10ml vial (20mg/10ml)<br />1 x 25ml vial (50mg/25ml)<br />1 x 50ml vial (100mg/ 50ml)<br />1 x 100ml vial (200mg/100ml)<br />5 and 10ml vials: Type I tubular glass vial with either teflon-coated rubber stopper or siliconised rubber stopper with teflon film on plug surface and aluminium flip-off white seal.<br />25ml vial: Type I tubular glass vial with either teflon-coated rubber stopper or siliconised rubber stopper with teflon film on plug surface and aluminium flip-off white/royal blue seal.<br />50ml vial: Type I clear moulded glass vial with either teflon-coated rubber stopper or siliconised rubber stopper with teflon film on plug surface and aluminium flip-off royal blue seal.<br />100ml vial: Type I clear moulded glass vial with either teflon-coated rubber stopper or siliconised rubber stopper with teflon film on plug surface and aluminium flip-off white / royal blue seal.<br />Pack size: 1 vial.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epirubicin Hydrochloride 2mg/ml Injection may be further diluted in Glucose 5% or Sodium Chloride 0.9% and administered as an intravenous infusion. For information on the stability of the infusion solutions, please refer to section 6.3.<br />The solution for injection or infusion contains no preservative and any unused portion of the vial should be discarded immediately in accordance with local requirements.<br />Guidelines for the safe handling and disposal of antineoplastic agents:<br />1. If an infusion solution is to be prepared, this should be performed by trained personnel under aseptic conditions.<br />2. Preparation of an infusion solution should be performed in a designated aseptic area.<br />3. Adequate protective disposable gloves, goggles, gown and mask should be worn.<br />4. Precautions should be taken to avoid the medicinal product accidentally coming into contact with the eyes. In the event of contact with the eyes, irrigate with large amounts of water and/or 0.9% sodium chloride solution. Then seek medical evaluation by a physician.<br />5. In case of skin contact, thoroughly wash the affected area with soap and water or Sodium Bicarbonate solution. However, do not abrade the skin by using a scrub brush. Always wash hands after removing gloves.<br />6. Spillage or leakage should be treated with dilute Sodium Hypochlorite (1% available Chlorine) solution, preferably by soaking, and then water. All cleaning materials should be disposed of as detailed below.<br />7. Pregnant staff should not handle the cytotoxic preparation.<br />8. Adequate care and precautions should be taken in the disposal of items (syringes, needles etc) used to reconstitute and/or dilute cytotoxic medicinal products. Any unused product or waste material should be&nbsp;disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, United Kingdom
Tel: +44 208 863 1427
Fax: +44 208 863 1426
E-mail: mena-info@accord-healthcare.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>